Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-chagas disease drug discovery

Journal of Medicinal Chemistry

Volumn 53, Issue 10, 2010, Pages 3887-3898

  Kraus, James M ^a   Tatipaka, Hari Babu ^a   McGuffin, Sarah A ^a   Chennamaneni, Naveen Kumar ^a   Karimi, Mandana ^a   Arif, Jenifer ^a   Verlinde, Christophe L M J ^b   Buckner, Frederick S ^a   Gelb, Michael H ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(2 AMINO 5 BROMOPHENYL)(3 CHLORO 2 METHYLPHENYL)METHANONE; (3 METHYL 3H IMIDAZOL 4 YL) 4 TOLYLMETHANONE; (3 METHYL 3H IMIDAZOL 4 YL)(4 TRIFLUOROMETHYLPHENYL)METHANONE; (4 CHLOROPHENYL)(1 ETHYL 1H IMIDAZOL 5 YL)METHANONE; (4 CHLOROPHENYL)(1 METHYL 1H IMIDAZOL 5 YL)METHANONE; (4 ETHYLPHENYL)(3 METHYL 3H IMIDAZOL 4 YL)METHANONE; (4 ISOPROPYLPHENYL)(3 METHYL 3H IMIDAZOL 4 YL)METHANONE; 1 TRIPHENYLMETHYL 4 IMIDAZOLE CARBOXALDEHYDE; 2 AMINO 5 BROMO N METHOXY N METHYLBENZAMIDE; 4 (3 CHLORO 2 METHYLPHENYL) 6 ((4 CHLOROPHENYL)(ETHOXY)(1 METHYL 1H IMIDAZOL 5 YL)METHYL) 1 METHYLQUINOLIN 2(1H) ONE; 4 (3 CHLORO 2 METHYLPHENYL) 6 ((4 CHLOROPHENYL)(HYDROXY)(1 METHYL 1H IMIDAZOL 5 YL)METHYL) 1 METHYLQUINOLIN 2(1H) ONE; 4 (3 CHLORO 2 METHYLPHENYL) 6 ((4 CHLOROPHENYL)(HYDROXY)(1 METHYL 1H IMIDAZOL 5 YL)METHYL) 2 METHOXYQUINOLINE; 4 (3 CHLORO 2 METHYLPHENYL) 6 ((4 CHLOROPHENYL)(HYDROXY)(1 METHYL 1H IMIDAZOL 5 YL)METHYL)QUINOLIN 2(1H) ONE; 4 (3 CHLORO 2 METHYLPHENYL) 6 ((4 CHLOROPHENYL)(METHYLAMINO) (1 METHYL 1H IMIDAZOL 5 YL)METHYL) 1 METHYLQUINOLIN 2(1H) ONE; 4 (3 CHLORO 2 METHYLPHENYL) 6 ((4 CHLOROPHENYL)(PROPOXY)(1 METHYL 1H IMIDAZOL 5 YL)METHYL) 1 METHYLQUINOLIN 2(1H) ONE; 4 CHLORO N METHOXY N METHYLBENZAMIDE.; 4 TOLYL (1 TRITYL 1 H IMIDAZOL 4 YL)METHANONE; 6 BROMO 4 (2,6 DIFLUOROPHENYL) 2 OXOTETRAHYDROQUINOLINE; 6 BROMO 4 (2,6 DIFLUOROPHENYL)QUINOLIN 2(1H) ONE; 6 BROMO 4 (3 CHLORO 2 METHYLPHENYL) 2 METHOXYQUINOLINE; 6 BROMO 4 (3 CHLORO 2 METHYLPHENYL)QUINOLIN 2(1H) ONE; 6 BROMO N 2,6 DIFLUOROCINNAMOYLANILIDE; ANTINEOPLASTIC AGENT; CYTOCHROME P450; KETONE DERIVATIVE; PROTEIN FARNESYLTRANSFERASE; QUINOLINE DERIVATIVE; STEROL 14ALPHA DEMETHYLASE; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; CHAGAS DISEASE; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTROSPRAY MASS SPECTROMETRY; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; TRYPANOSOMA CRUZI;

3T3 CELLS; ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; CHAGAS DISEASE; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; ISOENZYMES; MICE; MODELS, MOLECULAR; PROTEIN BINDING; QUINOLONES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 77952732116     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm9013136     Document Type: Article

References (11)

1. Division of Parasitic Diseases CfDC. Chagas Disease. http://www.cdc.gov/ chagas/.
2. Pecoul, B; Chirac, P; Trouiller, P; Pinel, J. Access to Essential Drugs in Poor Countries. A Lost Battle? JAMA, J. Am. Med. Assoc. 1999, 281, 361-367 (Pubitemid 29061041)
3. Gelb, M. H.; Hol, W. G. Drugs To Combat Tropical Protozoan Parasites Science 2002, 297, 343-344
4. Kohl, N. E.; Mosser, S. D.; deSolms, J; Giuliani, E. A.; Pompliano, D. L.; Graham, S. L. Selective Inhibition of ras -Dependent Transformation by a Farnesyl Transferase Inhibitor Science 1993, 260, 1934-1937
5. Buckner, F. S.; Verlinde, C. L. M. J.; La Flamme, A. C.; Van Voorhis, W. C. Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase Antimicrob. Agents Chemother. 1996, 40, 2592-2597
6. Hucke, O; Gelb, M. H.; Verlinde, C. L. M. J.; Buckner, F. S. The Protein Farnesyltransferase Inhibitor Tipifarnib as a New Lead for the Development of Drugs against Chagas Disease J. Med. Chem. 2005, 48, 5415-5418
7. Karp, J. E.; Kaufmann, S. H.; Adjei, A. A.; Lancet, J. E.; Wright, J. J.; End, D. W. Current status of clinical trials of farnesyltransferase inhibitors Curr. Opin. Oncol. 2001, 13, 470-476
8. Reid, T. S.; Beese, L. S. Crystal structures of the anticancer clinical candidates R115777 (tipifarnib) and BMS-214662 complexed with protein farnesyltransferase suggests a mechanism of FTI selectivity Biochemistry 2004, 43, 6877-6884
9. Kraus, J. M.; Verlinde, CLMJ; Karimi, M; Lepesheva, G. I.; Gelb, M. H.; Buckner, F. S. Rational modification of a candidate cancer drug for use against Chagas disease J. Med. Chem. 2008, 52, 1639-1647
10. Venet, M.; End, D.; Angibaud, P. Farnesyl protein transferase inhibitor Zarnestra R115 Curr. Top. Med. Chem. 2003, 1095-1102
11. Suryadevara, P. K.; Olepus, S; Lockman, J. W.; Ohkanda, J; Karimi, M; Verlinde, C. L. M. J.; Kraus, J. M.; Schoepe, J.; Van Voorhis, W. C.; Hamilton, A. D.; Buckner, F. S.; Gelb, M. H. J. Med. Chem. 2009, 52, 3703-3715